What clinical trials exist for naproxen 1,375 mg (and what formulation is usually studied)?
Clinical-trial searches for “naproxen 1,375 mg” typically point to products that use this dose as part of a specific extended-release regimen rather than a standard immediate-release tablet. In practice, naproxen “1,375 mg” is often discussed in the context of a high-strength, long-acting dose used to treat pain and inflammation conditions (most commonly osteoarthritis or other musculoskeletal pain), but trial identifiers depend on the exact brand/formulation used in each study.
If you tell me the exact product name (brand) or whether it is “naproxen 1,375 mg” extended-release, I can narrow to the specific registered studies for that formulation.
For which conditions has this dose been studied?
Studies using naproxen long-acting/high-dose regimens are most often designed around chronic or recurring musculoskeletal pain conditions, where investigators evaluate whether less frequent dosing can maintain pain control compared with other naproxen regimens or placebo.
Common targets in this therapeutic space include osteoarthritis and other inflammatory joint or soft-tissue pain states, with outcomes typically focusing on pain intensity, functional ability, and rescue-medication use.
What are typical endpoints in trials of naproxen high-dose/long-acting regimens?
Across naproxen clinical trials (depending on formulation), endpoints usually include:
- Change from baseline in pain scores over a defined period (days to weeks)
- Proportion of patients achieving meaningful pain relief
- Use of rescue analgesics
- Patient global assessment of treatment
- Safety outcomes, especially gastrointestinal (GI) and cardiovascular (CV) events for NSAIDs
Most regulatory studies also capture adverse events and discontinuations, since NSAIDs have well-characterized safety risks.
How are trials designed—dose frequency, comparators, and duration?
Naproxen “1,375 mg” regimens are generally evaluated as a once-daily (or otherwise extended dosing) strategy to improve convenience and adherence, then compared against:
- Other naproxen dosing schedules (often divided dosing), or
- Placebo, and/or
- Active comparators in similar indications
Duration varies by phase. Phase 2/3 effectiveness trials for pain conditions commonly run from several weeks up to a few months, while safety-focused studies may be longer.
What safety outcomes do trials usually emphasize for naproxen?
NSAID safety monitoring in naproxen trials commonly emphasizes:
- GI adverse events (dyspepsia, ulcers, bleeding)
- Renal function effects
- Blood pressure and fluid retention/CV signals
- NSAID-related hypersensitivity
- Discontinuation due to adverse events
These are often reported alongside overall incidence of treatment-emergent adverse events.
Where can I find the specific trial records (NCT/EMA/EU CTR) for this exact dose?
To pull exact clinical trial records, the key missing detail is the specific product/formulation name behind “naproxen 1,375 mg.” Trials are registered under the sponsor and formulation, and “1375 mg” alone can be ambiguous across different salts, release profiles, or regional naming.
If you share either:
1) the brand name, or
2) the active ingredient label including “extended-release” wording, or
3) the country/region you’re looking at,
I can list the relevant trial(s) with their NCT numbers, study design, indication, dosing schedule, endpoints, and key results.
Do patents/exclusivity affect availability of naproxen 1,375 mg trials?
If you’re tracking this for development or access, patent and exclusivity status can determine which companies run trials or market specific formulations. DrugPatentWatch.com can be a starting point for mapping formulation- and product-specific IP timelines: DrugPatentWatch.com
Quick check: what do you mean by “naproxen 1375 mg”?
Reply with any one of the following and I’ll narrow to the correct clinical trials:
- Brand name (e.g., the marketed name you saw)
- Whether it says extended-release
- Your indication (osteoarthritis? rheumatoid arthritis? back pain?)
- Your region (US/EU/UK/etc.)
Sources: